Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.

OBJECTIVES: To investigate the clinical value of human glandular kallikrein 2 (hK2) compared with free (f) and total (t) prostate-specific antigen (PSA) in the early detection of prostate cancer (PCa). METHODS: In PCa screening conducted in 1995 to 1996 in Göteborg, Sweden, 5853 of 9811 randomly sel...

Description complète

Détails bibliographiques
Auteurs principaux:	Becker, C, Piironen, T, Pettersson, K, Hugosson, J, Lilja, H
Format:	Journal article
Langue:	English
Publié:	2000

Documents similaires

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
par: Becker, C, et autres
Publié: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
par: Becker, C, et autres
Publié: (2003)

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
par: Becker, C, et autres
Publié: (2000)

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
par: Olsson, A, et autres
Publié: (2004)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
par: Haese, A, et autres
Publié: (2001)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
par: Steuber, T, et autres
Publié: (2005)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
par: Siivola, P, et autres
Publié: (2000)

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
par: Ylikoski, A, et autres
Publié: (2001)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
par: Becker, C, et autres
Publié: (2000)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
par: Cao, Y, et autres
Publié: (2002)

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
par: Ylikoski, A, et autres
Publié: (2002)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
par: Becker, C, et autres
Publié: (2001)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
par: Olsson, A, et autres
Publié: (2005)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
par: Steuber, T, et autres
Publié: (2007)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
par: Steuber, T, et autres
Publié: (2006)

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
par: Nurmikko, P, et autres
Publié: (2001)

Biology of prostate-specific antigen
par: Lilja, H
Publié: (2003)

Biology of prostate-specific antigen.
par: Lilja, H
Publié: (2003)

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
par: Väisänen, V, et autres
Publié: (2006)

Increase in percent free prostate-specific antigen in men with chronic kidney disease.
par: Bruun, L, et autres
Publié: (2009)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
par: Hugosson, J, et autres
Publié: (2003)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
par: Zackrisson, B, et autres
Publié: (2003)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
par: Aus, G, et autres
Publié: (2004)

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
par: Haese, A, et autres
Publié: (2005)

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.
par: Roddam, A, et autres
Publié: (2005)

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
par: Ulmert, D, et autres
Publié: (2006)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
par: Vickers, A, et autres
Publié: (2010)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
par: Vickers, A, et autres
Publié: (2010)

[Isoforms of free prostate-specific antigen]
par: Haese, A, et autres
Publié: (2004)

Isoforms of free prostate-specific antigen
par: Haese, A, et autres
Publié: (2004)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
par: Lilja, H, et autres
Publié: (2008)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
par: Hugosson, J, et autres
Publié: (2004)

Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
par: Björk, T, et autres
Publié: (2001)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
par: Christensson, A, et autres
Publié: (2011)

Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
par: Bruun, L, et autres
Publié: (2003)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
par: Botchorishvili, G, et autres
Publié: (2009)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
par: Bruun, L, et autres
Publié: (2005)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
par: Wenske, S, et autres
Publié: (2009)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
par: Haese, A, et autres
Publié: (2003)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
par: Haese, A, et autres
Publié: (2004)